Update shared on05 Sep 2025
Cipher Pharmaceuticals' future P/E has risen sharply, indicating increased valuation relative to earnings, while the net profit margin is stable, resulting in no change to the consensus analyst price target at CA$17.90.
What's in the News
- Cipher Pharmaceuticals is actively seeking accretive acquisitions and in-licensing opportunities, with a strategic focus on complementary U.S.-based assets and companies.
- The company is prioritizing capital allocation through share repurchases, debt repayment, and targeted acquisitions.
- Completed the repurchase of 230,278 shares (0.9%) for CAD 2.93 million under the normal course issuer bid.
Valuation Changes
Summary of Valuation Changes for Cipher Pharmaceuticals
- The Consensus Analyst Price Target remained effectively unchanged, at CA$17.90.
- The Future P/E for Cipher Pharmaceuticals has significantly risen from 23.09x to 31.86x.
- The Net Profit Margin for Cipher Pharmaceuticals remained effectively unchanged, at 26.96%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.